Loading patent…
OwnerRolando Perex Rodriguez, Gisela Maria Gonzalez Marinello +2inventors
InventorsRolando Perex Rodriguez, Gisela Maria Gonzalez Marinello, Tania Crobet Ramos, Irene Beausoleil Del Gado
Estimating the term…
The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.
A combination useful for immunotherapy, where this combination has an effect on growth and/or proliferation of cells, whose growth is dependent on the interaction between a receptor and its ligand, in the receptor tyrosine kinase system (RTK), this combination includes:
A treatment combination useful for immunotherapy, where this combination has an effect on growth and/or proliferation of cells, whose growth is dependent on the interaction between a receptor and its ligand, in the system of receptor tyrosine kinases (RTK), this combination including:
A combination useful for immunotherapy, where this combination has an effect on growth and/or proliferation of cells, whose growth is dependent on the interaction between a receptor and its ligand, in the system of receptor protein tyrosine kinases (RTK), this combination includes:
An immunotherapy combination according claim to 24 where the vaccine contains conjugated proteins p64K and EGF as active principle.
A method to control growth and/or proliferation of cells whose growth is dependent on the interaction between a receptor and its ligand, in the receptor tyrosine kinase (RTK) system, this method including the treatment with one of the therapeutic combinations defined in any one of the preceding claims.
Dependencies are inferred from the claim text.